These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27626268)

  • 1. [Antidotes to novel direct oral anticoagulants].
    Khorev NG; Momot AP; Kon'kova VO
    Angiol Sosud Khir; 2016; 22(3):177-83. PubMed ID: 27626268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery.
    Milling TJ; Ziebell CM
    Trends Cardiovasc Med; 2020 Feb; 30(2):86-90. PubMed ID: 30952383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.
    Enriquez A; Lip GY; Baranchuk A
    Europace; 2016 Jul; 18(7):955-64. PubMed ID: 25816811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel oral anticoagulants--key messages for the angiologist.
    Haas S; Spannagl M; Schellong SM
    Vasa; 2012 May; 41(3):177-91. PubMed ID: 22565619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring and reversal strategies for new oral anticoagulants.
    Vanden Daelen S; Peetermans M; Vanassche T; Verhamme P; Vandermeulen E
    Expert Rev Cardiovasc Ther; 2015 Jan; 13(1):95-103. PubMed ID: 25431993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
    Eriksson BI; Quinlan DJ; Eikelboom JW
    Annu Rev Med; 2011; 62():41-57. PubMed ID: 21226611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific antidotes in development for reversal of novel anticoagulants: a review.
    Gomez-Outes A; Suarez-Gea ML; Lecumberri R; Terleira-Fernandez AI; Vargas-Castrillon E
    Recent Pat Cardiovasc Drug Discov; 2014; 9(1):2-10. PubMed ID: 25494843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of action and clinical use of specific reversal agents for non-vitamin K antagonist oral anticoagulants.
    Andresen K; Atar D; Gjertsen E; Ghanima W; Roseth S; Johansen OE
    Scand Cardiovasc J; 2018 Jun; 52(3):156-162. PubMed ID: 29569500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral anticoagulants and status of antidotes for the reversal of bleeding risk.
    Ebright J; Mousa SA
    Clin Appl Thromb Hemost; 2015 Mar; 21(2):105-14. PubMed ID: 25115762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
    Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
    Int J Clin Pharmacol Ther; 2015 Mar; 53(3):211-9. PubMed ID: 25295718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidotes to non-vitamin K oral anticoagulants: necessary or not?
    Proietti M; Lip GY
    Expert Opin Pharmacother; 2015; 16(11):1573-6. PubMed ID: 26077323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
    Escolar G; Diaz-Ricart M; Arellano-Rodrigo E
    Drugs Today (Barc); 2017 May; 53(5):271-282. PubMed ID: 28650000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of the new oral anticoagulants: opportunities and challenges.
    Yeh CH; Hogg K; Weitz JI
    Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1056-65. PubMed ID: 25792448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bleeding and antidotes in new oral anticoagulants.
    Majeed A; Schulman S
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of the Pharmacology of the Emerging Possibilities of the Direct Oral Anticoagulants' Reversal.
    Samos M; Stanciakova L; Skornova I; Bolek T; Kovar F; Stasko J; Galajda P; Mokan M; Kubisz P
    Curr Drug Metab; 2017; 18(7):643-650. PubMed ID: 28412907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pros and cons of new oral anticoagulants.
    Bauer KA
    Hematology Am Soc Hematol Educ Program; 2013; 2013():464-70. PubMed ID: 24319220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Bleeding Associated with New Oral Anticoagulants.
    Franchini M; Bonfanti C; Mannucci PM
    Semin Thromb Hemost; 2015 Oct; 41(7):788-801. PubMed ID: 26408923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
    Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
    Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New oral anticoagulants in atrial fibrillation.
    Turpie AG
    Eur Heart J; 2008 Jan; 29(2):155-65. PubMed ID: 18096568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.